PEA15 and early-onset autosomal dominant Alzheimer disease: PEA15 was also found to be expressed in plaque-associated reactive astrocytes in post-mortem human Alzheimer’s disease (AD) tissue, so it was proposed as a biomarker of AD, along with other pathological hallmarks, to assess the severity of the disease progress at the time of death [24].